Stellate Ganglion Block to Augment Trauma-focused Therapy Among Veterans With PTSD
Key facts
- Who runs it
- Ohio State University
- Where
- Columbus, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 85 people enrolled
- Started
- 3 Jan 2022
- Ended
- 31 Mar 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Cognitive Processing Therapy (CPT)
- Stellate Ganglion Block
- Record updated
- 3 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- 18 years of age or older
- Prior or current service in the U.S. military
- Diagnosis of PTSD within the last month
- Ability to speak and understand the English language
- Stable psychotropic medication dosing for at least 3 months
- Ability to complete the informed consent process
Who cannot take part
- Prior SGB treatment or CPT treatment
- History of schizophrenia, another psychotic disorder, or bipolar disorder
- Moderate or severe symptoms of a substance use disorder within the preceding 30 days
- Any ongoing stressor or condition deemed by the investigators to place the participant at risk for injury or a poor outcome
- Moderate or severe traumatic brain injury
- Severe suicide risk warranting suicide-focused treatment and/or inpatient hospitalization
- Impaired mental status that precludes the ability to provide informed consent
Where in United States
- The Ohio State UniversityColumbus, United States
About the trial
What the trial wants to find out
Our long-term goal is to improve clinical outcomes among patients receiving psychological treatment for posttraumatic stress disorder (PTSD). The primary objective of this project is to examine if stellate ganglion block (SGB) improves outcomes among military personnel and veterans receiving cognitive processing therapy (CPT), an empirically-supported psychological treatment for PTSD. To accomplish this objective, we will enroll adult military personnel and veterans with a current diagnosis of PTSD and/or subthreshold PTSD, provide CPT sessions over two weeks, administer SGB during or after CPT, and repeatedly assess key outcomes during follow-up.
The 2 groups in the trial
- Stellate ganglion block (SGB) treatment during cognitive processing therapy (CPT)Treatment being tested
Participants will receive 12 sessions of cognitive processing therapy (CPT) for PTSD combined with SGB during the first week of CPT.
Treatment: Cognitive Processing Therapy (CPT) and Stellate Ganglion Block
- SGB three months after completing CPTTreatment being tested
Participant will receive 12 sessions of cognitive processing therapy (CPT) for PTSD and will receive SGB three months after completing the CPT sessions.
Treatment: Cognitive Processing Therapy (CPT) and Stellate Ganglion Block
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 3 July 2025